SCHEMBL632333

SCHEMBL632333

C[C@@H](CO)Nc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.56
TSHR P16473 4/20 0.55
ALDH1A1 P00352 4/20 0.55
CYP3A4 P08684 3/20 0.55
ALOX15 P16050 3/20 0.55
HSD17B10 Q99714 3/20 0.55
ALOX12 P18054 2/20 0.55
HIF1A Q16665 2/20 0.55
MAPK1 P28482 1/20 0.55
KCNH3 Q9ULD8 2/20 0.51
L3MBTL1 Q9Y468 3/20 0.48
THRB P10828 2/20 0.48
LMNA P02545 1/20 0.48
RECQL P46063 1/20 0.48
ATM Q13315 1/20 0.48
TP53 P04637 1/20 0.48
HSP90AA1 P07900 1/20 0.48
CASP1 P29466 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GAA P10253 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL632334 1.00 TDP1 (0.56) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL632612 1.00 TDP1 (0.56) TDP1TSHRALDH1A1CYP3A4ALOX15
Hydrochloric Acid SCHEMBL7447818 0.98 KCNH3 (0.54) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL2388601 0.83 TDP1 (0.52) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL2386760 0.83 TDP1 (0.52) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL17046082 0.80 TSHR (0.71) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL5176869 0.80 ALDH1A1 (0.52) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL21256944 0.80 ALDH1A1 (0.52) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL172358 0.79 ALDH1A1 (0.77) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL13776661 0.79 ALDH1A1 (0.77) TDP1TSHRALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116202846-B Method for identifying artery and vein 河北医科大学第二医院 2024-03-22 CN disclosed
CN-116202846-A Method for identifying artery and vein 河北医科大学第二医院 2023-06-02 CN disclosed
EP-4135740-A1 AEROSOLIZED FORMULATIONS OF HIV PROTEASE INHIBITORS FOR THE TREATMENT OF AIRWAY REFLUX The Medical College of Wisconsin, Inc. (US) 2023-02-22 EP disclosed
WO-2021212022-A1 AEROSOLIZED FORMULATIONS OF HIV PROTEASE INHIBITORS FOR THE TREATMENT OF AIRWAY REFLUX THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2021-10-21 WO disclosed
CN-107365368-B Asperphenamate synthesis related protein, coding gene and application thereof 中国科学院微生物研究所 2020-09-08 CN disclosed
EP-2475361-B1 N-SUBSTITUTED BENZENEPROPANAMIDES FOR USE IN THE TREATMENT OF PAIN AND INFLAMMATION NOVAREMED LTD (IL) 2019-11-06 EP disclosed
US-20160317479-A1 METHOD OF TREATING OR PREVENTING PAIN NOVAREMED LTD. (IL) 2016-11-03 US disclosed
EP-1750691-B1 COMPOUNDS FOR TREATMENT OF AIDS AND OTHER DISEASES NOVAREMED LTD (IL) 2016-08-10 EP disclosed
US-9199917-B2 N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation NOVAREMED LIMITED (IL) 2015-12-01 US disclosed
EP-2655344-B1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIV CATHOLIQUE LOUVAIN (BE) 2015-11-25 EP disclosed
US-20020156217-A1 Poly (phosphonoarylacetylene and chiral sensor comprising the same JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2002-10-24 US disclosed
EP-1231227-A1 POLY(PHOSPHONOARYLACETYLENE) AND CHIRAL SENSOR COMPRISING THE SAME Japan Science and Technology Corporation (JP) 2002-08-14 EP disclosed
WO-2001096278-A2 A NOVEL PROCESS FOR PREPARING SALMETEROL GLAXO GROUP LIMITED (GB) 2001-12-20 WO disclosed
EP-1073638-A1 HETEROCYCLICALLY SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 2001-02-07 EP disclosed
WO-1999054304-A1 HETEROCYCLICALLY SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 1999-10-28 WO disclosed
US-5846942-A Cholecystokinin antagonists, their preparation and therapeutic use WARNER-LAMBERT COMPANY (US) 1998-12-08 US disclosed
US-5593967-A Cholecystokinin antagonists, their preparation and therapeutic use WARNER-LAMBERT COMPANY (US) 1997-01-14 US disclosed
EP-0547178-A4 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER LAMBERT CO (US) 1994-07-06 EP disclosed
EP-0547178-A1 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1993-06-23 EP disclosed
WO-1992004045-A1 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1992-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160317479-A1 METHOD OF TREATING OR PREVENTING PAIN OPRL1, CALCA, CHRM1 TDP1 3366/4885TSHR 2742/4885ALDH1A1 1753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.